Skip to main content

Advertisement

SpringerLink
Log in

Feasibility of Breast Preservation in the Treatment of Occult Primary Carcinoma Presenting With Axillary Metastases

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: The objective of the study was to compare the treatment outcomes in patients with occult primary carcinoma with axillary lymph node metastasis who were treated with mastectomy or with intent to preserve the breast.

Methods: From 1951 to 1998, 479 female patients were registered with axillary lymph node metastasis from an unknown primary. After clinical workup, including mammography, 45 patients retained this diagnosis and received treatment for T0 N1–2 M0 carcinoma of the breast. Clinical and pathological data were collected retrospectively, and survival was calculated from the date of initial diagnosis using the Kaplan-Meier method. Median follow-up time was 7 years.

Results: Median age was 54 years (range, 32–79). Clinical nodal status was N1 in 71% and N2 in 29% of the patients. Surgical treatment was mastectomy in 29% and an intent to preserve the breast in 71% of the patients. Locoregional radiotherapy was used in 71% and systemic chemoendocrine therapy was used in 73% of the patients. Of the 13 mastectomy patients, only one had a primary tumor discovered in the specimen. Two patients (4%) were ultimately diagnosed with lung cancer and neuroendocrine tumor. No significant difference was detected between mastectomy and breast preservation in locoregional recurrence (15% versus 13%), distant metastases (31% versus 22%), or 5-year survival (75% vs. 79%). Regardless of surgical therapy, the most important determinant of survival was the number of positive nodes. Five-year overall survival was 87% with 1–3 positive nodes compared with 42% with ≥4 positive nodes (P < .0001).

Conclusions: Occult primary carcinoma with axillary metastases can be treated with preservation of the breast without a negative impact on local control or survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Abbruzzese A, Abbruzzese M, Hess K, Raber M, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12: 1272–80.

    PubMed  CAS  Google Scholar 

  2. Hainsworth J, Greco F. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993; 329: 257–63.

    PubMed  CAS  Google Scholar 

  3. Tench DW, Page DL. The unknown primary presenting with axillary lymphadenopathy.In: Bland KI, Copeland EM, eds. The Breast: Comprehensive Management of Benign and Malignant Diseases, vol 2. 2nd ed. Philadelphia: W.B. Saunders, 1998: 1447–52.

    Google Scholar 

  4. Owen HW, Dockerty MB, Gray HK. Occult carcinoma of the breast. Surg Gynecol Obstet 1954; 98: 302–8.

    PubMed  CAS  Google Scholar 

  5. Rosen PP. Axillary lymph node metastases in patients with occult noninvasive breast carcinoma. Cancer 1980; 46: 1298–1306.

    CAS  PubMed  Google Scholar 

  6. Patel J, Nemoto T, Rosner D, Dao TL, Pickren JW. Axillary lymph node metastasis from an occult breast cancer. Cancer 1981; 47: 2923–27.

    CAS  PubMed  Google Scholar 

  7. Halsted W. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907; 46: 1–19.

    PubMed  CAS  Google Scholar 

  8. Cameron HC. Some clinical facts regarding mammary cancer. BMJ 1909; 1: 577–82.

    Article  Google Scholar 

  9. Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA. Occult breast cancer presenting with axillary metastases: Updated management. Arch Surg 1990; 125: 210–14.

    PubMed  CAS  Google Scholar 

  10. Hainsworth JC, Greco FA. Management of patients with cancer of unknown primary site. Oncology 2000; 14: 563–79.

    PubMed  CAS  Google Scholar 

  11. Morrow M, Schmidt RA, Bucci C. Breast conservation for mammographically occult carcinoma. Ann Surg 1998; 227: 502–6.

    PubMed  CAS  Google Scholar 

  12. Ellerbroek N, Holmes F, Singletary E, Evans H, Oswald M, McNeese M. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 1990; 66: 1461–1467.

    CAS  PubMed  Google Scholar 

  13. American Joint Committee on Cancer. Breast.In: AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997.

    Google Scholar 

  14. Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 1989; 12: 123–28.

    Article  PubMed  CAS  Google Scholar 

  15. Buzdar AU, Hortobagyi GN, Kau SW, et al. Breast cancer adjuvant therapy at the M.D. Anderson Cancer Center: Results of four prospective studies.In: Salmon SE, ed. Adjuvant Therapy of Cancer VII. Philadelphia: JB Lippincott Company, 1993: 220–25.

    Google Scholar 

  16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 185: 1457–81.

    Google Scholar 

  17. Fortunato L, Sorrento JJ, Golub RA. Occult breast cancer: A case report and review of the literature. N Y State J Med 1992; 92: 555–57.

    PubMed  CAS  Google Scholar 

  18. Meterissian S, Fornage BD, Singletary SE. Clinically occult breast carcinoma: Diagnostic approaches and role of axillary node dissection. Ann Surg Oncol 1995; 2: 314–18.

    PubMed  CAS  Google Scholar 

  19. Rosen PP, Kimmel M. Occult breast carcinoma presenting with axillary lymph node metastases: A follow-up of 48 patients. Hum Pathol 1990; 21: 518–23.

    PubMed  CAS  Google Scholar 

  20. van Ooijen B, Bontenbal M, Henzen-Logmans SC. Axillary nodal metastases from an occult primary consistent with breast carcinomas. Br J Surg 1993; 80: 1299–1310434_2001_Article_425.

    PubMed  CAS  Google Scholar 

  21. Feigenberg Z, Zer M, Dintsman M. Axillary metastases from an unknown primary source: A diagnostic and therapeutic approach. Isr J Med Sci 1976; 12: 1151–58.

    Google Scholar 

  22. Merson M, Andreola S, Galimberti V, Bufalino R, Marchini S, Veronesi U. Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer 1992; 70: 504–8.

    CAS  PubMed  Google Scholar 

  23. Campana F, Fourquet A, Ashby MA, et al. Presentation of axillary lymphadenopathy without detectable primary (T0N1b breast cancer): Experience at Institut Curie. Radiother Oncol 1989; 15: 321–5.

    PubMed  CAS  Google Scholar 

  24. Fourquet A, De la Rochefordiere A, Campana F. Occult primary cancer with axillary metastases.In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999: 703–7.

    Google Scholar 

  25. Vilcoq JR, Calle R, Ferme F, Veith F. Conservative treatment of axillary adenopathy due to probable subclinical breast cancer. Arch Surg 1982; 117: 1136–38.

    PubMed  CAS  Google Scholar 

  26. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 1980; 45: 2917–24.

    PubMed  CAS  Google Scholar 

  27. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181–7.

    PubMed  CAS  Google Scholar 

  28. Henderson IC, Berry D, Demetri G, et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Oncol 1998; 17: 390a

    Google Scholar 

  29. Gianni L, Capri G, Valagussa P, Bonadonna G. Putting taxanes to work in2 operable breast cancer: A search for selective indications from empirical studies. Recent Results Cancer Res 1998; 152: 314–22.

    PubMed  CAS  Google Scholar 

  30. Nabholtz JM, Mackey J, Smylie M, Tonkin K. Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer. Semin Oncol 1998; 25: 27–31.

    PubMed  CAS  Google Scholar 

  31. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998; 351: 1451–67.

    Google Scholar 

  32. Anonymous. NSABP halts B-14 trial: No benefit seen beyond 5 years of tamoxifen use (news). J Natl Cancer Inst 1995; 87: 1829.

    Google Scholar 

  33. Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005–18.

    PubMed  CAS  Google Scholar 

  34. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997; 15: 1385–94.

    CAS  Google Scholar 

  35. Griem KL, Henderson C, Gelman R, et al. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 1987; 5: 1546–55.

    PubMed  CAS  Google Scholar 

  36. Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996; 334: 1356–61.

    Article  CAS  PubMed  Google Scholar 

  37. Buzdar A, Kau S, Smith T, et al. The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer. Cancer 1993; 71: 3680–84.

    PubMed  CAS  Google Scholar 

  38. Leonard CE, Wood ME, Zhen B, et al. Does administration of chemotherapy prior to radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control? J Clin Oncol 1995; 13: 2906–15.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

    Georges Vlastos MD, Marina E. Jean MD, Attiqa N. Mirza MD, Nadeem Q. Mirza MD, MPH, Henry M. Kuerer MD, PhD, Frederick C. Ames MD, Kelly K. Hunt MD, Merrick I. Ross MD & S. Eva Singletary MD

  2. Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

    Thomas A. Buchholz MD

  3. Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

    Aman U. Buzdar MD

  4. Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, TX, 77030

    S. Eva Singletary MD

Authors
  1. Georges Vlastos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marina E. Jean MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Attiqa N. Mirza MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nadeem Q. Mirza MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Henry M. Kuerer MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Frederick C. Ames MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kelly K. Hunt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Merrick I. Ross MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Thomas A. Buchholz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Aman U. Buzdar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S. Eva Singletary MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vlastos, G., Jean, M.E., Mirza, A.N. et al. Feasibility of Breast Preservation in the Treatment of Occult Primary Carcinoma Presenting With Axillary Metastases. Ann Surg Oncol 8, 425–431 (2001). https://doi.org/10.1007/s10434-001-0425-6

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10434-001-0425-6

Key Words:

Search

Navigation